RecruitingNot ApplicableNCT06482138

Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation

Dysfunction of Olfaction After SARS-CoV-2 Infection: Morphological and Histomolecular Investigation of Olfactory Cleft Biopsies and Cytobrushes


Sponsor

Universitaire Ziekenhuizen KU Leuven

Enrollment

240 participants

Start Date

Jan 24, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Investigation of the mechanisms of persistent SARS-CoV-2 associated olfactory dysfunction (OD) in patients with well-documented olfactory function. The investigators plan to collect olfactory cleft biopsies and cytobrushes in COVID-19 patients and controls.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria2

  • Olfactory Dysfunction group: Presence of evident OD (Parosmia, Threshold-Discrimination-Identification (TDI)-score ≤24, Subjective abnormal quantitative olfactory function; measured by a visual analogue score (VAS) of smell impairment ≥5/10
  • Control group: No OD (TDI-score \>30.5.)

Exclusion Criteria3

  • Presence of concomitant nasal mucosal pathology that might affect olfactory function or bias the study investigations
  • Use of anticoagulation therapy
  • Allergy to local anesthetics

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBiopsy and Cytobrush

Collection of olfactory cleft biopsies and cytobrushes


Locations(7)

Cliniques Universitaires Saint-Luc

Brussels, Brussels Capital, Belgium

UZ/KU Leuven

Leuven, Vlaams-Brabant, Belgium

AZ Sint-Jan Brugge

Bruges, West-Vlaanderen, Belgium

University Hospital Carl Gustav Carus

Dresden, Dresden, Germany

Max Planck Research Unit for Neurogenetics

Frankfurt am Main, Frankfurt, Germany

Hôpitaux Universitaires de Genève

Geneva, Canton of Geneva, Switzerland

University of Zurich and University Hospital Zurich

Zurich, Canton of Zurich, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06482138


Related Trials